Global Oxytocic Pharmaceuticals Market: Restraint
Problems with oxytocin preparations quality
Injectable oxytocin, given intravenously or intramuscularly, is recommended by the World Health Organization (WHO) as the first-line medicine for the prevention and treatment of postpartum haemorrhage. It is additionally used for the induction and augmentation of labour. Primary causes for substandard oxytocin quality are considered to be poor-quality manufacturing and/or product degradation in the supply chain. For instance, according to WHO (World Health Organization), 2021 report of Regulatory guidance for assessment and management of applications for marketing authorization of oxytocin, suggested the precautionary measures to be taken related to the supply chain, manufacturing and product degradation of Oxytocic pharmaceuticals. The causes of the issue with oxytocin preparations were also noted by the WHO.
Oxytocic Pharmaceuticals Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients